Solid Biosciences Inc
SLDB5.440USD
-0.030-0.55%
收盘 09/18, 16:00（美东）报价延迟15分钟
422.16M总市值
亏损市盈率 TTM
关于 Solid Biosciences Inc 公司
Solid Biosciences Inc. 是一家生命科学公司，致力于开发用于神经肌肉和心脏疾病的精准基因药物。该公司专注于推进一系列基因治疗候选药物，包括用于治疗杜氏肌营养不良症的 SGT-003、用于治疗儿茶酚胺能多形性室性心动过速的 SGT-501、用于治疗 BAG3 介导的扩张型心肌病的 AVB-401，以及用于治疗致命心脏疾病的其他资产。该公司还有两个心脏管线基因转移项目，用于 TNNT2 DCM 的 SGT-601 和用于 RBM20 DCM 的 SGT-701，均处于早期临床前开发阶段。它还有一个用于治疗弗里德赖希共济失调的神经肌肉基因转移项目。除了基因转移候选药物外，该公司还有专注于平台技术的开发项目，包括新型衣壳库和双基因表达，双基因表达是一种允许将多个转基因包装到一个衣壳中的技术。
公司简介
公司代码SLDB
公司名称Solid Biosciences Inc
上市日期Jan 26, 2018
CEOMr. Alexander (Bo) Cumbo
员工数量100
证券类型Ordinary Share
年结日Jan 26
公司地址500 Rutherford Avenue
城市CHARLESTOWN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02129
电话16173374680
网址https://www.solidbio.com/
公司代码SLDB
上市日期Jan 26, 2018
CEOMr. Alexander (Bo) Cumbo
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
132.92K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
122.12K
+3.89%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.72K
--
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
24.79K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
19.28K
+35.45%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
13.23K
+51.52%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+169.09%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
132.92K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
122.12K
+3.89%
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.72K
--
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
24.79K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
23.95K
+45.26%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
19.28K
+35.45%
收入明细
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
暂无数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Perceptive Advisors LLC
15.29%
Bain Capital Life Sciences Investors, LLC
10.16%
Invus Public Equities Advisors, LLC
9.52%
Adage Capital Management, L.P.
8.64%
RA Capital Management, LP
7.46%
其他
48.92%
持股股东
持股股东
占比
Perceptive Advisors LLC
15.29%
Bain Capital Life Sciences Investors, LLC
10.16%
Invus Public Equities Advisors, LLC
9.52%
Adage Capital Management, L.P.
8.64%
RA Capital Management, LP
7.46%
其他
48.92%
股东类型
持股股东
占比
Investment Advisor
38.52%
Hedge Fund
26.93%
Investment Advisor/Hedge Fund
15.50%
Private Equity
15.29%
Venture Capital
7.46%
Research Firm
2.08%
Individual Investor
0.56%
Bank and Trust
0.13%
Insurance Company
0.03%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
237
81.08M
104.59%
+27.37M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
2023Q2
203
16.54M
84.41%
-1.08M
2023Q1
234
16.00M
82.14%
-1.37M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Perceptive Advisors LLC
11.91M
15.36%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.21%
+2.88M
+57.15%
Mar 31, 2025
Invus Public Equities Advisors, LLC
7.42M
9.57%
+3.67M
+97.81%
Mar 31, 2025
Adage Capital Management, L.P.
6.73M
8.68%
+4.98M
+284.96%
Mar 31, 2025
RA Capital Management, LP
4.33M
5.59%
+90.74K
+2.14%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.92M
2.47%
+202.69K
+11.83%
Mar 31, 2025
The Vanguard Group, Inc.
2.46M
3.17%
+1.06M
+75.59%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.52M
4.54%
+3.47M
+7432.14%
Mar 31, 2025
Citadel Advisors LLC
1.89M
2.43%
+937.47K
+98.85%
Mar 31, 2025
Monashee Investment Management, LLC
1.67M
2.16%
+1.19M
+248.63%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
iShares Neuroscience and Healthcare ETF
0.94%
iShares Micro-Cap ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.04%
iShares Russell 2000 Value ETF
0.03%
iShares Russell 2000 ETF
0.02%
ProShares UltraPro Russell2000
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Global X Russell 2000 ETF
0.02%
查看更多
iShares Neuroscience and Healthcare ETF
占比0.94%
iShares Micro-Cap ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.05%
iShares Biotechnology ETF
占比0.04%
iShares Russell 2000 Value ETF
占比0.03%
iShares Russell 2000 ETF
占比0.02%
ProShares UltraPro Russell2000
占比0.02%
Invesco RAFI US 1500 Small-Mid ETF
占比0.02%
Global X Russell 2000 ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
公告日期
类型
比率
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
